Report of Foreign Issuer (6-k)
October 27 2016 - 7:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
October 27, 2016
PROQR
THERAPEUTICS N.V.
Zernikedreef 9
2333 CK
Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On October 27, 2016, ProQR Therapeutics N.V. issued a press releases titled, ProQR
Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous
D
F508 Cystic Fibrosis Patients. A copy of this press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROQR THERAPEUTICS N.V.
|
|
|
|
|
Date: October 27, 2016
|
|
|
|
By:
|
|
/s/ Smital Shah
|
|
|
|
|
|
|
Smital Shah
|
|
|
|
|
|
|
Chief Financial Officer
|
INDEX TO EXHIBITS
|
|
|
Number
|
|
Description
|
|
|
99.1
|
|
Press Release of ProQR Therapeutics N.V. dated October 27, 2016, titled ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous
D
F508 Cystic
Fibrosis Patients.
|
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Sep 2023 to Sep 2024